Technologies related to Rare Diseases

Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E
Ref: E-203-1997-0 | Updated: Jul 6, 2020
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-293-1999-0 | Updated: Jul 6, 2017
Blood-Based Assay for the Diagnosis and Monitoring of Hyposialylation Disorders
Ref: E-056-2013-0 | Updated: Jun 11, 2019
Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection
Ref: E-217-2004-0 | Updated: Jul 9, 2013
Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies
Ref: E-144-2012-0 | Updated: May 1, 2018
Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers
Ref: E-240-2011-0 | Updated: Apr 20, 2016
Encapsulated N-Acetylmannosamine or N-Acetylneuraminic Acid as a Therapeutic Agent for Increasing Sialylation in Certain Muscular Atrophies, Kidney Disorders, Cancers or Poor Immune Function
Ref: E-270-2011-0 | Updated: Sep 21, 2015
Multivalent Vaccines for Rabies Virus and Filoviruses
Ref: E-032-2011-0 | Updated: May 7, 2018
Full-Length Infectious cDNA Clones of Tick Borne Flavivirus
Ref: E-281-1998-0 | Updated: Sep 28, 2010
The Use of Recombinant Cholera Toxin-B for the Treatment of Inflammatory Bowel Disease
Ref: E-263-1999-0 | Updated: Jul 16, 2010
Moraxella Catarrhalis Lipooligosaccharide Based Conjugate Vaccines for the Prevention of Otitis Media and Respiratory Infections
Ref: E-264-1997-0 | Updated: Jul 1, 2014
Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4
Ref: E-089-2002-1 | Updated: May 6, 2016
Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region
Ref: E-159-2007-3 | Updated: Feb 28, 2011
Development of Dengue Virus Type 3 Vaccine Candidates
Ref: E-139-2006-0 | Updated: May 9, 2016
Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
Ref: E-120-2001-0 | Updated: Feb 28, 2011
Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines
Ref: E-268-2002-0 | Updated: Sep 1, 2008
Aquaporin 2 Polyclonal Antibodies
Ref: E-045-2008-0 | Updated: Dec 1, 2007
Peptide Mimotope Candidates for Otitis Media Vaccine
Ref: E-344-2002-0 | Updated: Jun 16, 2010
TMC1, a Deafness-Related Gene
Ref: E-168-2001-0 | Updated: May 1, 2007
Model for Study of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell Line with Tet-on-Regulated Gene Expression
Ref: E-049-2007-0 | Updated: May 14, 2018
Vaccine Production Strain for Acellular Pertussis Vaccine
Ref: E-159-1999-0 | Updated: Sep 16, 2015
Inhibitors of Formation of Protease Resistant Prion Protein
Ref: E-189-1998-0 | Updated: May 7, 2018
Antagonists of the Alpha Epsilon Beta 7 Integrin as Therapeutic Agents for Inflammatory Diseases
Ref: E-282-1998-0 | Updated: Jun 1, 1999
Nucleotide, Deduced Amino Acid Sequence, Isolation And Purification Of Heat-Shock Chlamydial Proteins
Ref: E-196-1989-0 | Updated: Feb 28, 2011
Identification Of The Gene Causing Familial Mediterranean Fever
Ref: E-257-1997-0 | Updated: May 14, 2016
AIB-1, A Steroid Receptor Co-Activator Amplified In Breast And Ovarian Cancer
Ref: E-018-1997-0 | Updated: May 16, 2016
MEN1, The Gene For Multiple Endocrine Neoplasia Type 1
Ref: E-094-1997-0 | Updated: Aug 1, 1997
Subscribe to Technologies related to Rare Diseases